Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

e, monitoring of growth in children taking GLEEVEC is recommended.

Cases of tumor lysis syndrome (TLS), including fatal cases, have been reported. The patients at risk of TLS are those with tumors having a high proliferative rate or high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.

In Ph+ CML trials(****), severe (NCI Grades 3/4) lab abnormalities—including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia (<1%-33%), and hepatotoxicity (approx 5%)—and severe adverse experiences (NCI Grades 3/4), including hemorrhage (1.8%-19%), fluid retention (eg, pleural effusion, pulmonary edema, and ascites) (2.5%-11%) and superficial edema (1.5%-6%), and musculoskeletal pain (2%-9%), were reported among patients receiving GLEEVEC. Severe fluid retention appears to be dose-related, was more common in the advanced phase studies (where the dosage was 600 mg/day), and is more common in the elderly.

There have also been reports, including fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure, and gastrointestinal (GI) perforation.

GLEEVEC is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6, and CYP2C9. Significant reductions in imatinib concentrations may occur when GLEEVEC is administered concomitantly with agents that are strong CYP3A4 inducers such as rifampin, St. John's wort, and enzyme-inducing anti-epileptic drugs, eg, phenytoin. The use of concomitant strong CYP3A4 inducers should be avoided. If patients must be administered a strong CYP3A4 inducer, the dosage of GLEEVEC should be increased by at least 50% and clinical response should be carefully monitored. Caution is recommended when GLEEVEC is administered with CYP3A4 inhibitors such as ketoconazole, with CYP2D6 substrates that have a narrow therapeutic window, or with CYP3A4 substrates that have a narrow therapeutic window. Other examples of commonly used drug
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the six months ended June 30, ... Canadian dollars and presented under International Financial Reporting ... , Announced top-line results related to ... for subjects enrolled in the Phase 2 iDEAL ...
(Date:8/29/2014)... Due to a misstatement posted by the ... Cell Technology Center, LLC ( ASCTC ) was reported as ... that might benefit ALS patients. Because of ASCTC's exclusive ... technologies and therapeutic applications, FRC listed ASCTC as one of ... who wish not to support research that requires the death ...
(Date:8/28/2014)... USA (PRWEB) August 28, 2014 SPIE ... of Physics and Optical Science and Director of the ... of North Carolina at Charlotte, and co-founder and Chairman ... to serve as the 2015 Vice President of SPIE, ... 2014 President Philip Stahl announced recent election results at ...
(Date:8/28/2014)... August 28, 2014 “This kit has an ... screen from 0 to 150 ppb,” said Mark Tess, PhD, ... significant benefit to plant owners and USDA-GIPSA inspection agencies that ... commodities. Testing can take place in a matter of minutes ... the plant test the feed and grain before accepting it, ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
... ABBOTT PARK, Ill., Sept. 17 The board of directors of ... 40 cents per share. , , This marks the ... cash dividend is payable Nov. 15, 2009, to shareholders of record at the ... has increased its dividend payout for 37 consecutive years - including an 11 ...
... , BOULDER, Colo., Sept. 17 ... awarded two Phase I Small Business Innovation Research (SBIR) grants ... Infectious Diseases (NIAID) of The National Institutes of Health (NIH). ... toxicology and pharmacology studies of the company,s proprietary long-acting G-CSF ...
... CHENGDU, China, Sept. 17 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical, ... and supplier of,modernized traditional Chinese medicine (,TCM,) based in ... call to discuss its fiscal,2009 fourth quarter and full ... 2009. , Interested parties may ...
Cached Biology Technology:Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating Acute Radiation Syndrome 2Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET 2
(Date:8/29/2014)... how the repeated climatic shifts over the last ... genetic diversity, a team of researchers led by ... Carnaval developed a new biodiversity metric called "phylogeographic ... the genetic variation within species is restricted in ... of biology, and 14 other researchers from institutions ...
(Date:8/29/2014)... news release is available in German . ... chemical signals between organisms is considered the oldest form ... interactions between conspecifics, for example, the sexual attraction between ... social responses and to coordinate reproductive behavior in males ... the University of the Algarve in Faro, Portugal, and ...
(Date:8/29/2014)... them, fold them: modern materials that are light, flexible ... artificial skin or electronic paper. , Making such concepts ... a new way of working with copper nanowires and ... , Previous success in the field of ultra-lightweight "aerogel ... gold and silver nanowires. , By turning instead ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Ready for mating at the right time 2Ready for mating at the right time 3Copper shines as flexible conductor 2
... of Pittsburgh of UPMC have discovered a unique population of ... used to treat muscle injuries and diseases such as heart ... muscle tissue, scientists in Children,s Stem Cell Research Center - ... isolated and characterized stem cells taken from blood vessels (known ...
... MOUNTAIN VIEW, Calif., Aug. 13 LaserCard,Corporation (Nasdaq: ... ID credentials,used in biometric identification, today announced the ... Middle Eastern government. A new centralized high-volume ... the optical memory and the eye-readable data of,this ...
... N.Y., Aug. 15 bioMETRX, Inc. (OTC,Bulletin Board: BMRX), ... announced that it is has provided notice to,certain holders ... holders,must surrender said warrants to the company by August ... series B $0.10 warrants that it,has elected to pay ...
Cached Biology News:Pittsburgh scientists identify human source of stem cells with potential to repair muscle 2Pittsburgh scientists identify human source of stem cells with potential to repair muscle 3LaserCard Corporation Announces Expansion of Middle East Project 2LaserCard Corporation Announces Expansion of Middle East Project 3bioMETRX, Inc. Calls Series B Warrants 2
... consists of an anodized aluminum body in ... Compounds embedded in polymerized matrix. It is ... and Synergy Multi-Detection Readers. This multi-functional test ... reducing the need for tedious wet testing. ...
... Safe DNA Gel Stain combo offers these benefits: ... same products separately Offers ... Eliminates risks to yourself, the ... fragments from 100 bp to >30 kb. UltraPure Agarose ...
... economical ICS-90 uses continuous chemical suppression and ... you fast, accurate determinations of common anions ... to operate, quick to equilibrate, and fully ... ICS-90 helps you achieve maximum sample throughput ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
Biology Products: